Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY: BHVN )

35.77 +0.02 (+0.07%)
Streaming Delayed Price Updated: 12:24 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
NYSE:BHVN Investor Alert: Investigation Concerning Possible Securities Laws Violations by Biohaven Ltd.
San Diego, CA -- (SBWIRE) -- 08/23/2023 -- Biohaven Ltd. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
$2M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
Biohaven Stock Is Plunging Today - Here's Why
Biohaven Ltd (NASDAQ: BHVN) shares are down after the company announced multiple  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Will The Dow Make History Today With A 14 Straight?
The blue-chip index is slightly above breakeven at midday, while the S&P 500 Index and Nasdaq Composite are higher after another batch of earnings. 
Via Talk Markets
Why Biohaven Stock Is Crashing Today
The clinical-stage biotech is going to remain in the clinical stage longer than it hoped. 
Via The Motley Fool
Why Biohaven Stock Caught Fire This Week
Investors are excited about the company's recent progress. 
Via The Motley Fool
Recap: Biohaven Q1 Earnings
Via Benzinga
Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
2 Growth Stocks With Major Incoming Catalysts
Binary events slated for July could quickly send these biotech stocks through the roof. 
Via The Motley Fool
Top 5 Health Care Stocks That May Crash This Month
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Tower Semiconductor, XP And 3 Stocks To Watch Heading Into Monday
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Top 5 Best And Worst U.S. Industry ETFs In Q1 2023: AI and Bank Turmoil Shaped Stock Returns
The first quarter of 2023 was positive for the U.S. stock market as a whole, with the S&P 500 index faithfully tracked by the SPDR S&P 500 ETF Trust (ARCA: SPY), rising by 6%. 
Via Benzinga
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product... 
Via Talk Markets
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
Via Benzinga
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy." 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
Via Benzinga
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'
Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Via Benzinga
Jim Cramer Says This Stock Is Dynamite: 'I Do Not Want You To Do A Thing Other Than Ride It'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Williams Companies, Inc. (NYSE: WMB) is "terrific." He recommended buying the stock. 
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
$41 Million Bet On This Biotechnology Stock? 3 Stocks Insiders Are Buying
Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday. 
Via Benzinga
Moderna, Amazon, Tesla, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.